U.S., Feb. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07414524) titled 'VLA1553-403 Pregnancy Surveillance Study' on Feb. 09.
Brief Summary: This post-marketing, observational study evaluates pregnancy and infant outcomes up to 12 weeks after delivery among women who received the chikungunya vaccine (VLA1553) during pregnancy or within 30 days before their last menstrual period. A matched comparator cohort of pregnant women vaccinated with routine, pregnancy-recommended vaccines (not exposed to VLA1553) is included. No study procedures beyond routine care are performed.
Study Start Date: March 31
Study Type: OBSERVATIONAL
Condition:
Chikungunya Virus Infection
Intervention:
BIOLOGICAL: Live-attenu...